Kymera Therapeutics

Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study

5th Annual Targeted Protein Degradation (TPD) Summit, October 25-28, 2022